

# PRODUCT INFORMATION



## PLX4032

Item No. 10618

**CAS Registry No.:** 918504-65-1  
**Formal Name:** N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide

**Synonyms:** RG-7204, Ro 51-85426, Vemurafenib

**MF:** C<sub>23</sub>H<sub>18</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S

**FW:** 489.9


**Purity:** ≥98%

**UV/Vis.:** λ<sub>max</sub>: 219, 252, 307 nm

**Supplied as:** A crystalline solid

**Storage:** -20°C

**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

PLX4032 is supplied as a crystalline solid. A stock solution may be made by dissolving the PLX4032 in the solvent of choice. PLX4032 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of PLX4032 in these solvents is approximately 1 and 20 mg/ml, respectively.

PLX4032 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PLX4032 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. PLX4032 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

PLX4032 is an orally bioavailable, ATP-competitive inhibitor of mutant V600E and wild type B-Raf kinases (IC<sub>50</sub>s = 31 and 100 nM, respectively).<sup>1</sup> It inhibits cell proliferation in a variety of cell lines expressing B-Raf<sup>V600E</sup> and synergizes strongly with taxol, vinblastine, and oxaliplatin in inhibiting the proliferation of B-Raf<sup>V600E</sup> transformed cancer cells.<sup>1</sup> PLX4032 is effective against the growth of tumors bearing the B-Raf<sup>V600E</sup> mutation.<sup>2-5</sup>

### References

1. Khazak, V., Atsaturov, I., Serebriiskii, I.G., et al. Selective Raf inhibition in cancer therapy. *Expert Opin. Ther. Targets* **11**(12), 1587-1609 (2007).
2. Flaherty, K.T., Puzanov, I., Kim, K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N. Engl. J. Med.* **363**(9), 809-819 (2010).
3. Bollag, G., Hirth, P., Tsai, J., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature* **467**, 596-599 (2010).
4. Coffee, E.M., Faber, A.C., Roper, J., et al. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF<sup>V600E</sup> colorectal cancer. *Clin. Cancer Res.* **19**(10), 2688-2698 (2013).
5. Huang, T., Karsy, M., Zhuge, J., et al. B-Raf and the inhibitors: From bench to bedside. *J. Hematol. Oncol.* **6**, 1-9 (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/26/2020

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM